Trials / Unknown
UnknownNCT03962010
A Phase 2, 12-Week, Double-Blind, Efficacy and Safety of GX-G6 in Patients With Uncontrolled Type 2 Diabetes Mellitus
A Phase 2, 12-Week, Double-Blind, Randomized, Parallel Group, Multi-Centre Study to Evaluate Efficacy and Safety of GX-G6 on Glycaemic Control Versus Placebo and Open-Label Dulaglutide in Patients With Uncontrolled Type 2 Diabetes Mellitus
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 78 (estimated)
- Sponsor
- Genexine, Inc. · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
GX-G6-002 is a Phase 2, 12-week, randomized, parallel group, multi-centre, double blind, placebo-controlled and an open-label active comparator study.
Detailed description
This study aims to establish the dose-response relationship of 4 dose cohorts of GX-G6 compared with double-blind placebo. These treatment cohorts will also be compared with open-label active control.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | GX-G6 | long acting anti-diabetic drug |
| DRUG | Control | Control |
Timeline
- Start date
- 2019-06-01
- Primary completion
- 2022-06-01
- Completion
- 2022-07-01
- First posted
- 2019-05-23
- Last updated
- 2019-05-23
Source: ClinicalTrials.gov record NCT03962010. Inclusion in this directory is not an endorsement.